Disease modification has become a well-established concept in several therapeutic areas;
however, no widely accepted definition of disease modification exists for SLE. We reviewed …

Despite an unprecedented rise in the number of biological therapies developed for systemic
lupus erythematosus (SLE) during the last decades, most randomised clinical trials (RCTs) …

Objectives To investigate the impact of remission and lupus low disease activity state
(LLDAS) on health-related quality of life (HRQoL) in systemic lupus erythematosus. Methods …

Background Since the development of the OMERACT Systemic Lupus Erythematosus (SLE)
Core Outcome Set (COS) in 1998, many new SLE domains have been identified and …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that has detrimental
effects on patient's health-related quality of life (HRQoL). Owing to its immense …

Patient-reported outcome (PRO) instruments are widely used to assess quality of life in
Systemic Lupus Erythematosus (SLE) research, and there is growing evidence for their use …

Systemic lupus erythematosus (SLE) remains a disease of high unmet clinical need.
Because of substantial patient heterogeneity, the execution of clinical trials that successfully …

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease, characterised by a
relapsing-remitting pattern of inflammatory activity, with each relapse contributing to …

Background Systemic lupus erythematosus (SLE), a systemic autoimmune disease with no
known cure, remains poorly understood and patients suffer from many gaps in care. Recent …

Objective As part of a Centers for Disease Control and Prevention–funded American
College of Rheumatology (ACR) initiative, we sought to develop quality measures related to …